Vishala T. Neppalli

<i>BCL2</i> Expression Is a Prognostic Marker for the Activated B-Cell–Like Type of Diffuse Large B-Cell Lymphoma

Javeed Iqbal, Vishala T. Neppalli, George W. Wright et al. · Journal of Clinical Oncology · 2006 · 303 citations · Full text

Medicine, Hematology, Oncology +12

NCCN Guidelines Insights: Multiple Myeloma, Version 3.2018

Shaji Kumar, Natalie S. Callander, Melissa Alsina et al. · Journal of the National Comprehensive Cancer Network · 2018 · 203 citations · Full text

Medicine, Hematology, Oncology +15

Antitumor Activity of the Investigational Proteasome Inhibitor MLN9708 in Mouse Models of B-cell and Plasma Cell Malignancies

Edmund C. Lee, Michael Fitzgerald, Bret Bannerman et al. · Clinical Cancer Research · 2011 · 106 citations

Medicine, Oncology, Pharmacology +16

NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2019

William G. Wierda, John C. Byrd, Jeremy S. Abramson et al. · Journal of the National Comprehensive Cancer Network · 2019 · 94 citations

Medicine, Hematology, Oncology +13

Reappraisal of the provisional entity primary cutaneous CD4+ small/medium pleomorphic T-cell lymphoma: A series of 10 adult and pediatric patients and review of the literature

Christian L. Baum, Brian K. Link, Vishala T. Neppalli et al. · Journal of the American Academy of Dermatology · 2011 · 74 citations

Medicine, Dermatology, Oncology +12